A phase II, single-arm, exploratory study of GEMOX combined with tislelizumab and donafenib in the perioperative treatment of potentially resectable intrahepatic cholangiocarcinoma with high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results